Having finally secured US approval for the post-operative nausea and vomiting (PONV) treatment Barhemsys, the UK's Acacia Pharma Group PLC can put into practice its well-laid plans to get the therapy into a sizeable market.
Interview: Acacia Seeks Access All Areas For PONV Drug Barhemsys
Third Time Lucky With FDA Approval
Acacia's bids to get the thumbs-up in the US for its post-operative nausea and vomiting therapy have finally borne fruit. CEO Mile Bolinder tells Scrip that his experienced team is now firmly focused on gaining as many hospital formulary approvals as possible for Barhemsys.
More from Drug Pricing
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
• By
CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.
More from Scrip
• By
Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.
• By
Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.
• By
Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.